Provided by Tiger Trade Technology Pte. Ltd.

TRAWS PHARMA

0.5874
-0.0046-0.78%
Volume:22.35K
Turnover:13.14K
Market Cap:9.03M
PE:-0.40
High:0.6100
Open:0.5925
Low:0.5802
Close:0.5920
52wk High:3.27
52wk Low:0.4301
Shares:15.37M
Float Shares:12.18M
Volume Ratio:0.31
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4733
EPS(LYR):0.8343
ROE:-433.36%
ROA:-99.40%
PB:5.34
PE(LYR):0.70

Loading ...

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

THOMSON REUTERS
·
Jun 22

Traws Pharma - Updated Data Package to Be Resubmitted to Mhra in Q3 2026

THOMSON REUTERS
·
Jun 22

Traws Pharma - Company to Initiate Profiling of Additional Molecules for Influenza Treatment Program

THOMSON REUTERS
·
Jun 22

Traws Pharma Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
Jun 18

Traws Pharma Inc : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS
·
Jun 18

Traws Pharma downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
Jun 18

BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex

Reuters
·
Jun 16

Traws Pharma Cut to Neutral From Buy by Ladenburg Thalmann

Dow Jones
·
Jun 16

Top Premarket Decliners

MT Newswires Live
·
Jun 15

BUZZ-U.S. STOCKS ON THE MOVE-Crypto stocks, Travel stocks, Micron

Reuters
·
Jun 15

Ladenburg Thalmann Downgrades Traws Pharma to Neutral From Buy, Price Target is $3

MT Newswires Live
·
Jun 15

Traws Pharma Delays Phase 2 Influenza Study After UK Regulatory Review; Shares Down Pre-Bell

MT Newswires Live
·
Jun 15

BUZZ-Traws Pharma slips after UK regulator derails key flu drug trial

Reuters
·
Jun 15

Traws Pharma influenza challenge study deferred following MHRA review

TIPRANKS
·
Jun 13

Traws Pharma Provides Regulatory Update on Influenza Program

THOMSON REUTERS
·
Jun 13

Traws Pharma - Cash Runway Extends to Q1 2027; Advancing Alternative Influenza Antiviral Candidates - SEC Filing

THOMSON REUTERS
·
Jun 13

Traws Pharma - Defers Planned Phase 2a Influenza Study of Tivoxavir Marboxil After Negative UK Mhra Review - SEC Filing

THOMSON REUTERS
·
Jun 13

Traws Pharma says UK MHRA review defers Phase 2a influenza challenge study for tivoxavir marboxil

Reuters
·
Jun 13

Traws Pharma advances dual-strike broad-spectrum antiviral program targeting Hantavirus and Ebola outbreaks

Reuters
·
May 27

Traws Pharma Inc - to Develop Local Manufacturing in Nigeria With Nafdac

THOMSON REUTERS
·
May 27